PMID- 22432554
OWN - NLM
STAT- MEDLINE
DCOM- 20120731
LR  - 20120321
IS  - 1751-7133 (Electronic)
IS  - 1527-5299 (Linking)
VI  - 18
IP  - 2
DP  - 2012 Mar-Apr
TI  - Initial description of cerebral oximetry measurement in heart failure patients.
PG  - 85-90
LID - 10.1111/j.1751-7133.2011.00284.x [doi]
AB  - Cerebral oximetry is a noninvasive technology using near-infrared spectroscopy 
      (NIRS) to monitor regional cerebral tissue oxygen saturation (SctO(2)). NIRS has 
      been widely used for assessing cerebral tissue oxygenation in a variety of 
      populations including the fields of neonatology, anesthesiology, neurology, and 
      cardiac surgery.However, little information has been reported on cerebral 
      oximetry in heart failure (HF) patients. In this observational study, we enrolled 
      30 patients (15 men) aged 23 to 82 years (mean 67 years) with stage C HF. All 
      patients had New York Heart Association (NYHA) functional class I to III. All 
      patients were on stable HF medical therapy. SctO(2) measurements were recorded 
      from the left and right forehead simultaneously, using FORE-SIGHT cerebral 
      oximeter (CAS Medical Systems Inc, Branford, CT). Feasible associations with 
      SctO(2) risk factors, known to correlate with HF, were recorded. The mean SctO(2) 
      value was 67.4% (range, 47.6%-76.3%), while the mean peripheral tissue saturation 
      (SpO(2)) was 97% (range, 92%-100%). The mean difference between cerebral and 
      peripheral tissue oxygenation (SpO(2)-SctO(2)) was 29.2% (range, 19.2%-51.4%). 
      There was also a significant positive correlation between SctO(2) and mean 
      arterial blood pressure (0.55, P<.01). Statistically significant lower SctO(2) 
      values were observed in patients with diabetes (P=.026; confidence interval [CI], 
      0.006-0.090) and in patients with dyslipidemia (P=.007; CI, 0.018-0.103). In this 
      initial description of SctO(2) in patients with stage C HF, we noted a wide range 
      of SctO(2) measurements. For most patients, there was a profound SpO(2)-SctO(2) 
      difference, despite near-normal peripheral oxygen saturations. The authors 
      suggest that SctO(2) is a potentially important biomarker to measure in HF 
      patients and may be a useful marker of target organ perfusion.
CI  - (c) 2012 Wiley Periodicals, Inc.
FAU - Rifai, Luay
AU  - Rifai L
AD  - Department of Internal Medicine, Advocate Christ Medical Center, University of 
      Illinois, Chicago, IL, USA. lrifai@uic.edu
FAU - Winters, James
AU  - Winters J
FAU - Friedman, Eli
AU  - Friedman E
FAU - Silver, Marc A
AU  - Silver MA
LA  - eng
PT  - Journal Article
DEP - 20120216
PL  - United States
TA  - Congest Heart Fail
JT  - Congestive heart failure (Greenwich, Conn.)
JID - 9714174
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain/*blood supply
MH  - Confidence Intervals
MH  - Female
MH  - Health Status Indicators
MH  - Heart Failure/drug therapy/*pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oximetry/*instrumentation/methods
MH  - Risk Factors
MH  - Spectroscopy, Near-Infrared/instrumentation
MH  - Statistics as Topic
MH  - Time Factors
MH  - Young Adult
EDAT- 2012/03/22 06:00
MHDA- 2012/08/01 06:00
CRDT- 2012/03/22 06:00
PHST- 2012/03/22 06:00 [entrez]
PHST- 2012/03/22 06:00 [pubmed]
PHST- 2012/08/01 06:00 [medline]
AID - 10.1111/j.1751-7133.2011.00284.x [doi]
PST - ppublish
SO  - Congest Heart Fail. 2012 Mar-Apr;18(2):85-90. doi: 
      10.1111/j.1751-7133.2011.00284.x. Epub 2012 Feb 16.